Article in The EMBO journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Matthew C FlemingDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Kenneth H PearceDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Cyrus VaziriCurriculum in Genetics and Molecular Biology, Department of Pathology and Laboratory Medicine, and Curriculum in Toxicology, University of North Carolina, Chapel Hill, NC, 27599, USA.
Albert A BowersDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa A. Troester · 2001 to 2026
$36.3M
User Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI MALCOLM S. CAPEL · 2018 to 2026
$34.2M
MIRA Equipment SupplementR35GM125005 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Albert A Bowers · 2017 to 2026
$3.9M
Establishing MAGE-A4/RAD18 as a novel cancer-specific chemotherapeutic targetR01CA229530 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEARCE, KENNETH HUGH, VAZIRI, CYRUS · 2019 to 2023
$2.0M
Inhibiting Rev1-mediated translesion DNA synthesis for cancer therapyR01CA279034 · NCI · DUKE UNIVERSITY · PI Jiyong Hong, Pei Zhou · 2024 to 2026
$1.6M
HHS | NIH | National Cancer Institute (NCI) CA229530HHS | NIH | National Cancer Institute (NCI) CA279034HHS | NIH | National Institute of General Medical Sciences (NIGMS) GM125005NCI NIH HHS R01 CA229530NCI NIH HHS R01 CA279034NIEHS NIH HHS P30 ES010126NIGMS NIH HHS P30 GM124165NIGMS NIH HHS R35 GM125005
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
Protein BindingBinding SitesCrystallography, X-RayDNA-Binding ProteinsHumansModels, MolecularNeoplasm ProteinsProtein ConformationDNA-Binding ProteinsNeoplasm Proteins
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Crystal structure of MAGEA4 MHD-RAD18 R6BD reveals a flipped binding mode compared to AlphaFold2 prediction. · full record | OpenQuestion